AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AZN
- Rev/Share 18.2261
- Book/Share 14.4548
- PB 5.8709
- Debt/Equity 0.7343
- CurrentRatio 0.8629
- ROIC 0.1094
- MktCap 262527910268.0
- FreeCF/Share 2.8142
- PFCF 30.0926
- PE 31.6503
- Debt/Assets 0.2921
- DivYield 0.0185
- ROE 0.1984
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Oct. 16, 2025 |
| Initiation | AZN | Exane BNP Paribas | -- | Outperform | -- | $75 | April 15, 2025 |
| Upgrade | AZN | UBS | Neutral | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | AZN | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Sept. 13, 2024 |
News
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
AstraZeneca unveils expanded manufacturing facility in Texas
Published: October 15, 2025 by: Business Wire
Sentiment: Neutral
COPPELL, Texas--(BUSINESS WIRE)--AstraZeneca today announces the unveiling of its newly-expanded, state-of-the-art manufacturing facility in Coppell, Texas. The expansion project will double the production of Lokelma for the benefit of patients in the United States and around the world. The investment of $445 million to expand the facility follows the groundbreaking last week at AstraZeneca's manufacturing facility in Albemarle County, Virginia. Both are part of AstraZeneca's $50 billion invest.
Read More
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.
Read More
AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.
Published: October 10, 2025 by: Market Watch
Sentiment: Positive
AstraZeneca PLC looks poised to announce a deal with U.S. President Donald Trump that's focused on lowering drug prices, in a move that would see the British drugmaker follow in the footsteps of Pfizer Inc.
Read More
AstraZeneca is the latest major drugmaker to strike a deal with the Trump administration on lowering U.S. drug prices, according to a person familiar with the matter
Published: October 10, 2025 by: WSJ
Sentiment: Positive
The agreement follows last week's deal with Pfizer.
Read More
Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports
Published: October 10, 2025 by: CNBC
Sentiment: Positive
The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported. President Donald Trump has already agreed to a similar pact with Pfizer, which will sell discounted drugs to Medicaid patients through a website called TrumpRx.gov.
Read More
AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump
Published: October 09, 2025 by: Reuters
Sentiment: Positive
AstraZeneca broke ground on a new plant in Virginia on Thursday and said it would spend $4.5 billion on the facility as drugmakers look to respond to President Donald Trump's call for more medicines to be made in the U.S. and at lower costs.
Read More
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
Published: October 09, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces that it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments. This is part of the historic $50 billion investment announced in July 2025. The new facility will be located at Rivanna Futures in Albemarle County and is expected to create approximately 3,600 direct and indirect job.
Read More
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
AstraZeneca shares leap with FDA set to review drug to treat breast cancer
Published: October 01, 2025 by: Market Watch
Sentiment: Positive
AstraZeneca shares rallied on Wednesday after the U.K. giant and its Japanese partner said the Food and Drug Administration was reviewing one of its drugs to treat breast cancer.
Read More
AstraZeneca's US listing may pull other firms from London in its wake
Published: September 30, 2025 by: Reuters
Sentiment: Negative
AstraZeneca's move to upgrade its listing in the U.S. risks pulling liquidity away from London's stock market and could pave the way for other large companies to follow suit, analysts, investors and advisers said.
Read More
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products puts over 50% of its free cash flow at risk, despite ongoing U.S. manufacturing expansion. Sanofi's high-margin Dupixent and AZN's broad U.S. portfolio are also vulnerable, though both are investing in U.S. production to seek exemptions.
Read More
AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices
Published: September 26, 2025 by: WSJ
Sentiment: Negative
AstraZeneca said it will offer its asthma and diabetes drugs at an up to 70% discount in the U.S. ahead of a Trump administration deadline for pharmaceutical companies to cut drug prices.
Read More
AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
Published: September 26, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery. AstraZeneca Direct will support people living with chronic conditions such as asthma, diabetes, heart failure and chronic kidney disease, and people seeking flu protection. Starting October 1, 2025, eligible patients with prescrip.
Read More
AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.
Read More
AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.
Read More
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Astrazeneca (AZN) is a Strong Value Stock
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca wins CHMP backing for label expansions of Koselugo in adult NF1 PN patients and Tezspire in chronic rhinosinusitis with nasal polyps.
Read More
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
Published: September 22, 2025 by: Benzinga
Sentiment: Positive
AstraZeneca Plc AZN and Amgen Inc.'s AMGN Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
3 Potential Biotech Acquisition Targets
Published: September 19, 2025 by: Seeking Alpha
Sentiment: Positive
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have good balance sheets. The article below discusses three promising names that have bright futures but also could attract interest from larger names in the industry.
Read More
AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy
Published: September 19, 2025 by: Seeking Alpha
Sentiment: Positive
AstraZeneca PLC is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. AZN's financials show improving margins, rising EPS, and efficient R&D investment, supporting steady share price appreciation and dividend growth. The company is fairly valued, possibly slightly undervalued, with a buy rating for long-term, lower-risk investors; shares below $70 would be a Strong Buy.
Read More
PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Negative
AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.
Read More
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
Published: September 17, 2025 by: Benzinga
Sentiment: Negative
AstraZeneca Plc AZN released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).
Read More
UK drug giants in the spotlight as part of latest sector review
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
The UK's two big drugmakers came under the spotlight in Berenberg's latest review of the pharmaceuticals sector. AstraZeneca PLC (LSE:AZN) gets a clear thumbs-up with a 'buy' rating and price target of £142, implying around 24% upside from £114.
Read More
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca's SAPHNELO® (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo.1 The safety profile observed in the interim analysis was consistent with the known clinical profile of SAP.
Read More
AstraZeneca lupus drug Saphnelo shows promise in self-injection trial
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) has reported positive results from a late-stage study of Saphnelo, its treatment for systemic lupus erythematosus (SLE), showing the drug was effective when given as a self-administered injection under the skin. The phase III TULIP-SC trial met its main goal at an interim analysis, demonstrating that patients receiving subcutaneous Saphnelo had a statistically significant and clinically meaningful reduction in disease activity compared with placebo.
Read More
AstraZeneca's asthma drug fails main goal of COPD study
Published: September 17, 2025 by: Reuters
Sentiment: Negative
AstraZeneca said on Wednesday that its asthma drug Fasenra failed the main goal of a late-stage study in patients with chronic obstructive pulmonary disease (COPD).
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Pascal Claude Roland Soriot
- Employees 94300